LTR Pharma is a Clinical Stage Biopharmaceutical Company
Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.
SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects
LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years
worldwide expected cases by 2025
minute effectiveness
projected global market value 2024
ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.
This week, LTR Pharma announced the key findings of its pivotal clinical study of SpontanÒ, demonstrating that the nasal spray is absorbed 470% faster than oral tablets. Executive Chairman, Lee Rodne, recently spoke with @ausbiz anchor Nadine Blayney about the significance of these findings, the Company’s plans to target the
LTR Pharma’s announcement of key results from its pivotal study of SPONTAN has been shared in industry publication, Biotech Daily. Click to read the article.
LTR Pharma has today announced key results from its pivotal study demonstrating that SPONTAN® Nasal Spray works significantly faster than the oral tablet, achieving 470% faster absorption than oral vardenafil tablets and reaching its peak concentration in 12 min vs 56 min. SPONTAN also displayed clinically relevant comparable bioavailability, with
9/204 Alice Street, Brisbane QLD 4000
Phone: 1800 519 711